Changes in US stocks | PFE.US (PFE.US) fell more than 4%, and the company expects revenue growth to slow in 2026

The Zhitong Finance App learned that on Tuesday, Pfizer (PFE.US) fell more than 4% to $25.27. According to the news, Pfizer predicts that sales growth will be minimal or no next year as the company strives to update its popular drug product line through a series of expensive acquisitions. Pfizer said in a statement on Tuesday that 2026 revenue is expected to be between US$59.5 billion and US$62.5 billion, which is roughly in line with Wall Street's expectations. This year's sales are expected to be $62 billion, in line with the scope of the company's guidance in early November. The company expects adjusted earnings per share to be between $2.80 and $3 next year.

CEO Albert Bourla is facing a critical moment to reinvigorate Pfizer, as demand for COVID-19 vaccines and therapeutics that drove the company's sales surge a few years ago is fading, and revenue from COVID-related products is still declining; Pfizer predicts that sales of these products will drop by about $1.5 billion to $5 billion next year.